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G-GH-3
A PILOT STUDY OF TRANSCATHETER ARTERIAL INTERFERON-EMBOLIZATION (TAIE) FOR
HEPATOCELLULAR CARCINOMA. MF Yuen1. C Ooi2, WM Wong1, OO Chan1, BCY Wong1 and CL
Lai1. Department of Medicine1 and Department of Diagnostic Radiology2, The University of Hong Kong, Queen
Mary Hospital, Hong Kong
Background: Interferon-alpha (IFN-a) is effective in a 30% of patients with hepatocellular carcinoma (HCC) when
given systemically using extremely high doses thrice weekly (Lai CL et al, Hepatology 1993). However, the side
effects were severe and the cost was high. Regional therapy through the transarterial route would concentrate the
IFN-a on the tumor cells, reduce the systemic side effects and require only one dose of IFN-a every 2-3 months.
We conduct a pilot study of transcatheter arterial interferon-embolization (TAIE), using IFN-a2b and gelfoam, for
the treatment of HCC to define the optimal dose and safety of IFN-a. Patients and methods: To date, a total of 13
patients with biopsy-proven HCC (M:F 11:2, median age 61 yrs) were recruited. Patients were randomized to
receive IFN-a2b 10MU/m2 (3 patients), 30MU/m2 (8 patients) or 50MU/m2 (2 patients) intraarterially. The complete
blood count, liver function tests, prothrombin time and alpha-fetoprotein (AFP) were monitored. The treatment was
given every 8 weeks. The side effects were closely monitored. Results: The median follow-up was 4 mths (range
1-12 mths). The mean diameter of HCC was 9.9 cm (range 3.5-22 cm). A total of 29 sessions of TAIE were
performed. For the 12 patients with baseline AFP > 20 ng/ml, all had a reduction of AFP after each session of TAIE.
3/12 (25%) patients had normalization of AFP. The median AFP levels dropped from 720 ng/ml to 365 ng/ml
(p=0.0747). 8 patients received 2 or more sessions of TAIE in whom the tumor response was assessed
angiographically. 3/8 (37.5%) patients had > 50% reduction in size of the index tumors, 4/8 (50%) patients had
static tumors and 1 (12.5%) patient had progressive tumors. In 3/8 (37.5%) patients the tumors became avascular
angiographically and were assessed as totally necrotic. 5 patients died (median survival 6 months): 2 of uncontrolled
HCC, 1 of brain metastasis, 1 of tumor lysis and 1 of ruptured HCC. The side effects included rigor usually lasting
only 1-2 hrs, and fever (median 6 days; range 0-21 days). There was no deterioration of liver function tests and
prothrombin time attributable to IFN-a. Conclusion: TAIE was effective in suppressing HCC. There was no liver
decompensation. The main side effect was fever. More long-term studies are required to assess the efficacy. This
study was supported by Schering-Plough Corporation
G-GH-4
SIGNIFICANCE OF HBSAG SEROCLEARANCE IN CHINESE PATIENTS WITH CHRONIC
HEPATITIS B VIRUS (HBV) INFECTION
MF Yuen. CW Siu, CL Lai. Department of Medicine, University of Hong Kong, Hong Kong.
Background: Loss of HBsAg is rare in Chinese with HBV infection since childhood. The clinical significance is
unknown. Aim: To study the liver function tests (LFT), HBV DNA levels and clinical outcome of patients with
HBsAg seroclearance. Patients and Methods: 63 Chinese with chronic HBV infection and subsequent loss of
HBsAg [M:F 42:21, median age 42 yrs (range 3-75.4 yrs), median follow-up 89.9 months! were studied. 63 HBV
patients who did not lose serum HBsAg matched for age, sex and HBeAg status were chosen for comparison.
Results: The median age of HBsAg seroclearance was 47.14 yrs (4.3-84.7 yrs). 4 patients had prior interferon
therapy. There was no significant difference in the LFT on presentation between those who lost HBsAg and those
who did not lose HBsAg. In the 15 patients positive for HBeAg on presentation, albumin, ALT and AST improved
after HBeAg seroconversion (46 vs. 45 g/L, p=0.041; 20 vs 276 U/L, p=0.001; 23 vs 210 U/L, p=0.001 respectively
compared to the levels on presentation). ALT and AST further improved after HBsAg seroclearance (12 vs. 20 U/L,
p=0.004; 17 vs. 23 U/L, p=0.008). In the 48 patients positive for anti-HBe on presentation, ALT improved after
HBsAg seroclearance compared with the levels on presentation (20 vs. 22 U/L, p=0.02). After HBsAg seroclearance,
HBV DNA levels were below the limit of detection in 26/39 (66.7%), between 0.5-1 pg/ml in 12/39 (30.8%) and
38.15 pg/ml in one patient. 7/63 (11.1%) had biochemical, ultrasonographic and/or histologic evidence of cirrhosis,
all detected before HBsAg seroclearance. One patient with ascites before HBsAg seroclearance continued to have
worsening ascites. Another developed hepatoma 20 months after HBsAg seroclearance. Conclusions: LFT on
presentation were not of predictive value for HBsAg seroclearance. Albumin, ALT and AST improved after HBeAg
seroconversion and further improved after HBsAg seroclearance. The majority of the patients who lost HBsAg had
low levels of viraemia. Cirrhosis developing before HBsAg seroclearance would continue to progress.
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